Literature DB >> 28667560

Cardiac Autoimmunity: Myocarditis.

William Bracamonte-Baran1, Daniela Čiháková2,3.   

Abstract

Myocarditis is the inflammation of the muscle tissues of the heart (myocardium). After a pathologic cardiac-specific inflammatory process, it may progress to chronic damage and dilated cardiomyopathy. The latter is characterized by systolic dysfunction, whose clinical correlate is heart failure. Nevertheless, other acute complications may arise as consequence of tissue damage and electrophysiologic disturbances. Different etiologies are involved in triggering myocarditis. In some cases, such as giant cell myocarditis or eosinophilic necrotizing myocarditis, it is an autoimmune process. Several factors predispose the development of autoimmune myocarditis such as systemic/local primary autoimmunity, viral infection, HLA and gender bias, exposure of cryptic antigens, mimicry, and deficient thymic training/Treg induction. Once the anti-myocardium autoimmune process is triggered, several components of the immune response orchestrate a sustained attack toward myocardial tissues with particular timing and immunopathogenic features. Innate response mediated by monocytes/macrophages, neutrophils, and eosinophils parallels the adaptive response, playing a final effector role and not only a priming function. Stromal cells like fibroblast are also involved in the process through specific cytokines. Furthermore, adaptive T cell responses have anti-paradigmatic features, as Th17 response is dispensable for acute myocarditis but is the main driver of the process leading to dilated cardiomyopathy. Humoral response, thought to be a bystander, is important in the appearance of late-stage hemodynamic complications. The complexity of that process, as well as the unspecific and variable clinical presentation, had generated difficulties for diagnosis and treatment, which remain suboptimal. In this chapter, we will discuss the most relevant immunopathogenic findings from a basic science and clinical perspective.

Entities:  

Keywords:  Adaptive response; Autoimmunity; Dilated cardiomyopathy; Myocarditis

Mesh:

Substances:

Year:  2017        PMID: 28667560      PMCID: PMC5706653          DOI: 10.1007/978-3-319-57613-8_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  163 in total

1.  Autoantibodies against the beta1 adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes.

Authors:  T Christ; E Wettwer; D Dobrev; E Adolph; M Knaut; G Wallukat; U Ravens
Journal:  J Mol Cell Cardiol       Date:  2001-08       Impact factor: 5.000

Review 2.  Macrophage diversity in cardiac inflammation: a review.

Authors:  Jobert G Barin; Noel R Rose; Daniela Ciháková
Journal:  Immunobiology       Date:  2011-06-30       Impact factor: 3.144

3.  Incidence, causes, and outcomes of dilated cardiomyopathy in children.

Authors:  Jeffrey A Towbin; April M Lowe; Steven D Colan; Lynn A Sleeper; E John Orav; Sarah Clunie; Jane Messere; Gerald F Cox; Paul R Lurie; Daphne Hsu; Charles Canter; James D Wilkinson; Steven E Lipshultz
Journal:  JAMA       Date:  2006-10-18       Impact factor: 56.272

4.  Association of HLA class II DRB1, DPA1 and DPB1 polymorphism with genetic susceptibility to idiopathic dilated cardiomyopathy in Chinese Han nationality.

Authors:  Wei Liu; Wei-Min Li; Shu-Sen Yang; Cheng Gao; Shao-Jun Li; Yue Li; Yi-Hui Kong; Run-Tao Gan
Journal:  Autoimmunity       Date:  2006-09       Impact factor: 2.815

Review 5.  Th1 and Th17 cells: adversaries and collaborators.

Authors:  Jesse M Damsker; Anna M Hansen; Rachel R Caspi
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

6.  Variations in the susceptibility to Coxsackievirus B3-induced myocarditis among different strains of mice.

Authors:  L J Wolfgram; K W Beisel; A Herskowitz; N R Rose
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

7.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators.

Authors:  J W Mason; J B O'Connell; A Herskowitz; N R Rose; B M McManus; M E Billingham; T E Moon
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

Review 8.  Adrenergic nervous system in heart failure: pathophysiology and therapy.

Authors:  Anastasios Lymperopoulos; Giuseppe Rengo; Walter J Koch
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

9.  Idiopathic dilated cardiomyopathy: lack of association between circulating organ-specific cardiac antibodies and HLA-DR antigens.

Authors:  A L Caforio; M Martinetti; G Schwarz; E Bonifacio; A Gavazzi; G Graziano; R Lorini; M Cuccia; W J McKenna; G F Bottazzo
Journal:  Tissue Antigens       Date:  1992-05

10.  Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy.

Authors:  Lei Wu; SuFey Ong; Monica V Talor; Jobert G Barin; G Christian Baldeviano; David A Kass; Djahida Bedja; Hao Zhang; Asfandyar Sheikh; Joseph B Margolick; Yoichiro Iwakura; Noel R Rose; Daniela Ciháková
Journal:  J Exp Med       Date:  2014-06-16       Impact factor: 14.307

View more
  49 in total

1.  An evidence for surface expression of an immunogenic epitope of sarcoplasmic/endoplasmic reticulum calcium-ATPase2a on antigen-presenting cells from naive mice in the mediation of autoimmune myocarditis.

Authors:  Rajkumar Arumugam; Bharathi Yalaka; Chandirasegaran Massilamany; M S Shihabudeen Haider Ali; Ninaad Lasrado; Sabarirajan Jayaraja; Jean-Jack Riethoven; Xinghui Sun; Jay Reddy
Journal:  Immunobiology       Date:  2019-12-13       Impact factor: 3.144

2.  Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.

Authors:  Han Zhu; Francisco X Galdos; Daniel Lee; Sarah Waliany; Yuhsin Vivian Huang; Julia Ryan; Katherine Dang; Joel W Neal; Heather A Wakelee; Sunil A Reddy; Sandy Srinivas; Lih-Ling Lin; Ronald M Witteles; Holden T Maecker; Mark M Davis; Patricia K Nguyen; Sean M Wu
Journal:  Circulation       Date:  2022-06-28       Impact factor: 39.918

Review 3.  Roles of Host Immunity in Viral Myocarditis and Dilated Cardiomyopathy.

Authors:  Lifang Zhao; Zhaoying Fu
Journal:  J Immunol Res       Date:  2018-05-07       Impact factor: 4.818

Review 4.  Infectious myocarditis: the role of the cardiac vasculature.

Authors:  Linde Woudstra; Lynda J M Juffermans; Albert C van Rossum; Hans W M Niessen; Paul A J Krijnen
Journal:  Heart Fail Rev       Date:  2018-07       Impact factor: 4.214

5.  Myocarditis: An Interleukin-1-Mediated Disease?

Authors:  Giacomo De Luca; Giulio Cavalli; Corrado Campochiaro; Moreno Tresoldi; Lorenzo Dagna
Journal:  Front Immunol       Date:  2018-06-13       Impact factor: 7.561

Review 6.  COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management.

Authors:  Yasar Sattar; Waqas Ullah; Hiba Rauf; Hafeez Ul Hassan Virk; Sunita Yadav; Medhat Chowdhury; Michael Connerney; Sahil Mamtani; Mohit Pahuja; Raj D Patel; Tanveer Mir; Talal Almas; Homam Moussa Pacha; M Chadi Alraies
Journal:  Int J Cardiol Heart Vasc       Date:  2020-07-14

7.  COVID-19 vaccine-induced myocarditis: Case report with literature review.

Authors:  Mahmoud Nassar; Nso Nso; Carlos Gonzalez; Sofia Lakhdar; Mohsen Alshamam; Mohammed Elshafey; Yousef Abdalazeem; Andrew Nyein; Benjamin Punzalan; Richard Jesse Durrance; Mostafa Alfishawy; Sanjiv Bakshi; Vincent Rizzo
Journal:  Diabetes Metab Syndr       Date:  2021-07-10

Review 8.  Sex differences in inflammation, redox biology, mitochondria and autoimmunity.

Authors:  Damian N Di Florio; Jon Sin; Michael J Coronado; Paldeep S Atwal; DeLisa Fairweather
Journal:  Redox Biol       Date:  2020-03-04       Impact factor: 11.799

Review 9.  Autoimmunity as the comet tail of COVID-19 pandemic.

Authors:  Rossella Talotta; Erle Robertson
Journal:  World J Clin Cases       Date:  2020-09-06       Impact factor: 1.337

10.  House Dust Mite Specific Antibodies induce Neutrophilic Inflammation in the Heart.

Authors:  Xiao Chen; Yuan-Yi Zhang; Dongting Ye; Gui Yang; Yan-Nan Song; Li-Hua Mo; Ping-Chang Yang; Jiang-Ping Song
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.